Sex and gender differences in HIV-1 infection

Clinical Science

Volumn 130, Issue 16, 2016, Pages 1435-1451

  Griesbeck, Morgane ^a   Scully, Eileen ^b   Altfeld, Marcus ^c  

^a Assistance publique Hôpitaux de Paris   (France)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

Author keywords

Acquisition; HIV 1; Immune activation; Oestrogen signalling; Sex; Viral loads

Indexed keywords

ALPHA INTERFERON; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CONTRACEPTIVE AGENT; SEX HORMONE;

ARTICLE; CYTOKINE RESPONSE; DISEASE COURSE; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOSTIMULATION; INFECTION PREVENTION; INFECTION SENSITIVITY; NONHUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; SIDE EFFECT; VIRAL CLEARANCE; VIRUS PATHOGENESIS; VIRUS TRANSMISSION; COMPARATIVE STUDY; DISEASE PREDISPOSITION; FEMALE; GENDER IDENTITY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

DISEASE SUSCEPTIBILITY; FEMALE; GENDER IDENTITY; HIV INFECTIONS; HIV-1; HUMANS; MALE; SEX FACTORS;

EID: 85014388249     PISSN: 01435221     EISSN: 14708736     Source Type: Journal    
DOI: 10.1042/CS20160112     Document Type: Article

References (198)

1. WHO (2014) Global Summary of the AIDS epidemic 2014, WHO-Department, UNAIDS
2. Bozzette, S.A., Berry, S.H., Duan, N., Frankel, M.R., Leibowitz, A.A., Lefkowitz, D., Emmons, C.A., Senterfitt, J.W., Berk, M.L., Morton, S.C. et al. (1998) The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N. Engl. J. Med. 339, 1897-1904.
3. Moore, J., Schuman, P., Schoenbaum, E., Boland, B., Solomon, L. and Smith, D. (1999) Severe adverse life events and depressive symptoms among women with, or at risk for, HIV infection in four cities in the United States of America. AIDS 13, 2459-2468.
4. Chaisson, R.E., Keruly, J.C. and Moore, R.D. (1995) Race, sex, drug use, and progression of human immunodeficiency virus disease. N. Engl. J. Med. 333, 751-756.
5. Lemp, G.F., Hirozawa, A.M., Cohen, J.B., Derish, P.A., McKinney, K.C. and Hernandez, S.R. (1992) Survival for women and men with AIDS. J. Infect. Dis. 166, 74-79.
6. Melnick, S.L., Sherer, R., Louis, T.A., Hillman, D., Rodriguez, E.M., Lackman, C., Capps, L., Brown, Jr, L.S., Carlyn, M., Korvick, J.A. et al. (1994) Survival and disease progression according to gender of patients with HIV infection. The Terry Beirn Community Programs for Clinical Research on AIDS. JAMA 272, 1915-1921.
7. WHO (2014) Global Update on the Health Sector Response to HIV 2014, WHO
8. Hawkins, C., Chalamilla, G., Okuma, J., Spiegelman, D., Hertzmark, E., Aris, E., Ewald, T., Mugusi, F., Mtasiwa, D., Fawzi, W. (2011) Sex differences in antiretroviral treatment outcomes among HIV-infected adults in an urban Tanzanian setting. AIDS 25, 1189-1197.
9. Klausner, J.D., Serenata, C., O'Bra, H., Mattson, C.L., Brown, J.W., Wilson, M., Mbengashe, T. and Goldman, T.M. (2011) Scale-up and continuation of antiretroviral therapy in South African treatment programs, 2005-2009. J. Acquir. Immune Defic. Syndr. 56, 292-295.
10. Stenehjem, E. and Shlay, J.C. (2008) Sex-specific differences in treatment outcomes for patients with HIV and AIDS. Expert. Rev. Pharmacoecon Outcomes Res. 8, 51-63.
11. Stringer, J.S., Zulu, I., Levy, J., Stringer, E.M., Mwango, A., Chi, B.H., Mtonga, V., Reid, S., Cantrell, R.A., Bulterys, M. et al. (2006) Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 296, 782-793.
12. Taylor-Smith, K., Tweya, H., Harries, A., Schoutene, E. and Jahn, A. (2010) Gender differences in retention and survival on antiretroviral therapy of HIV-1 infected adults in Malawi. Malawi Med. J. 22, 49-56.
13. Cornell, M., Schomaker, M., Garone, D.B., Giddy, J., Hoffmann, C.J., Lessells, R., Maskew, M., Prozesky, H., Wood, R., Johnson, L.F. et al. (2012) Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study. PLoS Med. 9, e1001304.
14. Norman, R., Matzopoulos, R., Groenewald, P. and Bradshaw, D. (2007) The high burden of injuries in South Africa. Bull. World Health Organ. 85, 695-702.
15. Klein, S.L., Schiebinger, L., Stefanick, M.L., Cahill, L., Danska, J., de Vries, G.J., Kibbe, M.R., McCarthy, M.M., Mogil, J.S., Woodruff, T.K. et al. (2015) Opinion: sex inclusion in basic research drives discovery. Proc. Natl. Acad. Sci. U.S.A. 112, 5257-5258.
16. Hladik, F. and McElrath, M.J. (2008) Setting the stage: host invasion by HIV. Nat. Rev. Immunol. 8, 447-457.
17. Patel, P., Borkowf, C.B., Brooks, J.T., Lasry, A., Lansky, A. and Mermin, J. (2014) Estimating per-act HIV transmission risk: a systematic review. AIDS 28, 1509-1519.
18. Nicolosi, A., Correa Leite, M.L., Musicco, M., Arici, C., Gavazzeni, G. and Lazzarin, A. (1994) The efficiency of male-to-female and female-to-male sexual transmission of the human immunodeficiency virus: a study of 730 stable couples. Italian Study Group on HIV Heterosexual Transmission. Epidemiology 5, 570-575.
19. UNAIDS (2013) Global Report: UNAIDS Report on the Global AIDS Epidemic 2013, UNAIDS
20. Quinn, T.C., Wawer, M.J., Sewankambo, N., Serwadda, D., Li, C., Wabwire-Mangen, F., Meehan, M.O., Lutalo, T., Gray, R.H. (2000) Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N. Engl. J. Med. 342, 921-929.
21. Chakraborty, H., Sen, P.K., Helms, R.W., Vernazza, P.L., Fiscus, S.A., Eron, J.J., Patterson, B.K., Coombs, R.W., Krieger, J.N. and Cohen, M.S. (2001) Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS 15, 621-627.
22. Pilcher, C.D., Tien, H.C., Eron, Jr, J.J., Vernazza, P.L., Leu, S.Y., Stewart, P.W., Goh, L.E. and Cohen, M.S. (2004) Brief but efficient: acute HIV infection and the sexual transmission of HIV. J. Infect. Dis. 189, 1785-1792.
23. Powers, K.A., Poole, C., Pettifor, A.E. and Cohen, M.S. (2008) Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis. 8, 553-563.
24. Hughes, J.P., Baeten, J.M., Lingappa, J.R., Magaret, A.S., Wald, A., de Bruyn, G., Kiarie, J., Inambao, M., Kilembe, W., Farquhar, C. et al. (2012) Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J. Infect Dis. 205, 358-365.
25. Farzadegan, H., Hoover, D.R., Astemborski, J., Lyles, C.M., Margolick, J.B., Markham, R.B., Quinn, T.C. and Vlahov, D. (1998) Sex differences in HIV-1 viral load and progression to AIDS. Lancet 352, 1510-1514.
26. Sterling, T.R., Lyles, C.M., Vlahov, D., Astemborski, J., Margolick, J.B. and Quinn, T.C. (1999) Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. J. Infect. Dis. 180, 666-672.
27. Bosch, R.J., Bennett, K., Collier, A.C., Zackin, R. and Benson, C.A. (2007) Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 44, 268-277.
28. Anastos, K., Gange, S.J., Lau, B., Weiser, B., Detels, R., Giorgi, J.V., Margolick, J.B., Cohen, M., Phair, J., Melnick, S. et al. (2000) Association of race and gender with HIV-1 RNA levels and immunologic progression. J. Acquir. Immune Defic. Syndr. 24, 218-226.
29. Katzenstein, D.A., Hammer, S.M., Hughes, M.D., Gundacker, H., Jackson, J.B., Fiscus, S., Rasheed, S., Elbeik, T., Reichman, R., Japour, A. et al. (1996) The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N. Engl. J. Med. 335, 1091-1098.
30. Sterling, T.R., Vlahov, D., Astemborski, J., Hoover, D.R., Margolick, J.B. and Quinn, T.C. (2001) Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N. Engl. J. Med. 344, 720-725.
31. Comparison of female to male and male to female transmission of HIV in 563 stable couples. European Study Group on Heterosexual Transmission of HIV (1992) BMJ 304, 809-813.
32. Porco, T.C., Martin, J.N., Page-Shafer, K.A., Cheng, A., Charlebois, E., Grant, R.M. and Osmond, D.H. (2004) Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 18, 81-88.
33. El-Sadr, W.M., Coburn, B.J. and Blower, S. (2011) Modeling the impact on the HIV epidemic of treating discordant couples with antiretrovirals to prevent transmission. AIDS 25, 2295-2299.
34. Cohen, M.S., Chen, Y.Q., McCauley, M., Gamble, T., Hosseinipour, M.C., Kumarasamy, N., Hakim, J.G., Kumwenda, J., Grinsztejn, B., Pilotto, J.H. et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 365, 493-505.
35. Boily, M.C., Baggaley, R.F., Wang, L., Masse, B., White, R.G., Hayes, R.J. and Alary, M. (2009) Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet. Infect. Dis. 9, 118-129.
36. Gray, R.H., Wawer, M.J., Sewankambo, N.K., Serwadda, D., Li, C., Moulton, L.H., Lutalo, T., Wabwire-Mangen, F., Meehan, M.P., Ahmed, S. et al. (1999) Relative risks and population attributable fraction of incident HIV associated with symptoms of sexually transmitted diseases and treatable symptomatic sexually transmitted diseases in Rakai District, Uganda. Rakai Project Team. AIDS 13, 2113-2123.
37. Piot, P. and Laga, M. (1989) Genital ulcers, other sexually transmitted diseases, and the sexual transmission of HIV. BMJ 298, 623-624.
38. Mayer, K.H. and Venkatesh, K.K. (2011) Interactions of HIV, other sexually transmitted diseases, and genital tract inflammation facilitating local pathogen transmission and acquisition. Am. J. Reprod. Immunol. 65, 308-316.
39. O'Farrell, N. (2001) Enhanced efficiency of female-to-male HIV transmission in core groups in developing countries: the need to target men. Sex. Transm. Dis. 28, 84-91.
40. Brown, J.M., Wald, A., Hubbard, A., Rungruengthanakit, K., Chipato, T., Rugpao, S., Mmiro, F., Celentano, D.D., Salata, R.S., Morrison, C.S. et al. (2007) Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe. AIDS 21, 1515-1523.
41. Rottingen, J.A., Cameron, D.W. and Garnett, G.P. (2001) A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm. Dis. 28, 579-597.
42. Kaul, R., Pettengell, C., Sheth, P.M., Sunderji, S., Biringer, A., MacDonald, K., Walmsley, S. and Rebbapragada, A. (2008) The genital tract immune milieu: an important determinant of HIV susceptibility and secondary transmission. J. Reprod. Immunol. 77, 32-40.
43. Zhu, J., Hladik, F., Woodward, A., Klock, A., Peng, T., Johnston, C., Remington, M., Magaret, A., Koelle, D.M., Wald, A. et al. (2009) Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat. Med. 15, 886-892.
44. Martin, Jr, H.L., Nyange, P.M., Richardson, B.A., Lavreys, L., Mandaliya, K., Jackson, D.J., Ndinya-Achola, J.O. and Kreiss, J. (1998) Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J. Infect. Dis. 178, 1053-1059.
45. Atashili, J., Poole, C., Ndumbe, P.M., Adimora, A.A. and Smith, J.S. (2008) Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS 22, 1493-1501.
46. Taha, T.E., Hoover, D.R., Dallabetta, G.A., Kumwenda, N.I., Mtimavalye, L.A., Yang, L.P., Liomba, G.N., Broadhead, R.L., Chiphangwi, J.D. and Miotti, P.G. (1998) Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS 12, 1699-1706.
47. Buve, A., Jespers, V., Crucitti, T. and Fichorova, R.N. (2014) The vaginal microbiota and susceptibility to HIV. AIDS 28, 2333-2344.
48. Anahtar, M.N., Byrne, E.H., Doherty, K.E., Bowman, B.A., Yamamoto, H.S., Soumillon, M., Padavattan, N., Ismail, N., Moodley, A., Sabatini, M.E. et al. (2015) Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity 42, 965-976.
49. Macklaim, J.M., Clemente, J.C., Knight, R., Gloor, G.B. and Reid, G. (2015) Changes in vaginal microbiota following antimicrobial and probiotic therapy. Microb. Ecol. Health Dis. 26, 27799.
50. Mingjia, L. and Short, R. (2002) How oestrogen or progesterone might change a woman's susceptibility to HIV-1 infection. Aust. N. Z. J. Obstet. Gynaecol. 42, 472-475.
51. Kaushic, C., Roth, K.L., Anipindi, V. and Xiu, F. (2011) Increased prevalence of sexually transmitted viral infections in women: the role of female sex hormones in regulating susceptibility and immune responses. J. Reprod. Immunol. 88, 204-209.
52. Francis, S.C., Looker, C., Vandepitte, J., Bukenya, J., Mayanja, Y., Nakubulwa, S., Hughes, P., Hayes, R.J., Weiss, H.A. and Grosskurth, H. (2015) Bacterial vaginosis among women at high risk for HIV in Uganda: high rate of recurrent diagnosis despite treatment. Sex. Transm. Infect. 92, 142-148
53. van de Wijgert, J.H., Verwijs, M.C., Turner, A.N. and Morrison, C.S. (2013) Hormonal contraception decreases bacterial vaginosis but oral contraception may increase candidiasis: implications for HIV transmission. AIDS 27, 2141-2153.
54. Wira, C.R., Fahey, J.V., Ghosh, M., Patel, M.V., Hickey, D.K. and Ochiel, D.O. (2010) Sex hormone regulation of innate immunity in the female reproductive tract: the role of epithelial cells in balancing reproductive potential with protection against sexually transmitted pathogens. Am. J. Reprod. Immunol. 63, 544-565.
55. Hu, J., Gardner, M.B. and Miller, C.J. (2000) Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J. Virol. 74, 6087-6095.
56. Hladik, F., Sakchalathorn, P., Ballweber, L., Lentz, G., Fialkow, M., Eschenbach, D. and McElrath, M.J. (2007) Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 26, 257-270.
57. Wieser, F., Hosmann, J., Tschugguel, W., Czerwenka, K., Sedivy, R. and Huber, J.C. (2001) Progesterone increases the number of Langerhans cells in human vaginal epithelium. Fertil. Steril. 75, 1234-1235.
58. Carias, A.M., McCoombe, S., McRaven, M., Anderson, M., Galloway, N., Vandergrift, N., Fought, A.J., Lurain, J., Duplantis, M., Veazey, R.S. et al. (2013) Defining the interaction of HIV-1 with the mucosal barriers of the female reproductive tract. J. Virol. 87, 11388-11400.
59. Dominguez, F., Galan, A., Martin, J.J., Remohi, J., Pellicer, A. and Simon, C. (2003) Hormonal and embryonic regulation of chemokine receptors CXCR1, CXCR4, CCR5 and CCR2B in the human endometrium and the human blastocyst. Mol. Hum. Reprod. 9, 189-198.
60. Prakash, M., Kapembwa, M.S., Gotch, F. and Patterson, S. (2002) Oral contraceptive use induces upregulation of the CCR5 chemokine receptor on CD4(+) T cells in the cervical epithelium of healthy women. J. Reprod. Immunol. 54, 117-131.
61. Sheffield, J.S., Wendel, Jr, G.D., McIntire, D.D. and Norgard, M.V. (2009) The effect of progesterone levels and pregnancy on HIV-1 coreceptor expression. Reprod. Sci. 16, 20-31.
62. Li, Q., Estes, J.D., Schlievert, P.M., Duan, L., Brosnahan, A.J., Southern, P.J., Reilly, C.S., Peterson, M.L., Schultz-Darken, N., Brunner, K.G. et al. (2009) Glycerol monolaurate prevents mucosal SIV transmission. Nature 458, 1034-1038.
63. Markle, J.G. and Fish, E.N. (2014) SeXX matters in immunity. Trends Immunol. 35, 97-104.
64. Naranbhai, V., Abdool Karim, S.S., Altfeld, M., Samsunder, N., Durgiah, R., Sibeko, S., Abdool Karim, Q. and Carr, W.H. (2012) Innate immune activation enhances HIV acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J. Infect. Dis. 206, 993-1001.
65. McLaren, P.J., Ball, T.B., Wachihi, C., Jaoko, W., Kelvin, D.J., Danesh, A., Kimani, J., Plummer, F.A. and Fowke, K.R. (2010) HIV-exposed seronegative commercial sex workers show a quiescent phenotype in the CD4+ T cell compartment and reduced expression of HIV-dependent host factors. J. Infect. Dis. 202 (Suppl 3), S339-S344.
66. Arnold, K.B., Burgener, A., Birse, K., Romas, L., Dunphy, L.J., Shahabi, K., Abou, M., Westmacott, G.R., McCorrister, S., Kwatampora, J. et al. (2016) Increased levels of inflammatory cytokines in the female reproductive tract are associated with altered expression of proteases, mucosal barrier proteins, and an influx of HIV-susceptible target cells. Mucosal Immunol. 9, 194-205.
67. Jewkes, R.K., Dunkle, K., Nduna, M. and Shai, N. (2010) Intimate partner violence, relationship power inequity, and incidence of HIV infection in young women in South Africa: a cohort study. Lancet 376, 41-48.
68. Kouyoumdjian, F.G., Calzavara, L.M., Bondy, S.J., O'Campo, P., Serwadda, D., Nalugoda, F., Kagaayi, J., Kigozi, G., Wawer, M. and Gray, R. (2013) Intimate partner violence is associated with incident HIV infection in women in Uganda. AIDS 27, 1331-1338.
69. Slaughter, L., Brown, C.R., Crowley, S. and Peck, R. (1997) Patterns of genital injury in female sexual assault victims. Am J. Obstet. Gynecol. 176, 609-616.
70. Roberts, L., Passmore, J.A., Mlisana, K., Williamson, C., Little, F., Bebell, L.M., Walzl, G., Abrahams, M.R., Woodman, Z., Abdool Karim, Q. et al. (2012) Genital tract inflammation during early HIV-1 infection predicts higher plasma viral load set point in women. J. Infect. Dis. 205, 194-203.
71. Enomoto, L.M., Kloberdanz, K.J., Mack, D.G., Elizabeth, D. and Weinberg, A. (2007) Ex vivo effect of estrogen and progesterone compared with dexamethasone on cell-mediated immunity of HIV-infected and uninfected subjects. J. Acquir. Immune Defic. Syndr. 45, 137-143.
72. Blish, C.A. and Baeten, J.M. (2011) Hormonal contraception and HIV-1 transmission. Am. J. Reprod. Immunol. 65, 302-307.
73. Baeten, J.M., Benki, S., Chohan, V., Lavreys, L., McClelland, R.S., Mandaliya, K., Ndinya-Achola, J.O., Jaoko, W. and Overbaugh, J. (2007) Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS 21, 1771-1777.
74. Heffron, R., Donnell, D., Rees, H., Celum, C., Mugo, N., Were, E., de Bruyn, G., Nakku-Joloba, E., Ngure, K., Kiarie, J. et al. (2012) Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect. Dis. 12, 19-26.
75. Gray, R.H. (2012) Use of hormonal contraceptives and risk of HIV-1 transmission. Lancet Infect. Dis. 12, 507, author reply 510-501.
76. Baeten, J.M., Lavreys, L., Sagar, M., Kreiss, J.K., Richardson, B.A., Chohan, B., Panteleeff, D., Mandaliya, K., Ndinya-Achola, J.O., Overbaugh, J. et al. (2005) Effect of contraceptive methods on natural history of HIV: studies from the Mombasa cohort. J. Acquir. Immune Defic. Syndr. 38 (Suppl 1), S18-S21.
77. Lavreys, L., Baeten, J.M., Kreiss, J.K., Richardson, B.A., Chohan, B.H., Hassan, W., Panteleeff, D.D., Mandaliya, K., Ndinya-Achola, J.O. and Overbaugh, J. (2004) Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women. J. Infect. Dis. 189, 303-311.
78. Lavreys, L., Baeten, J.M., Martin, Jr, H.L., Overbaugh, J., Mandaliya, K., Ndinya-Achola, J. and Kreiss, J.K. (2004) Hormonal contraception and risk of HIV-1 acquisition: results of a 10-year prospective study. AIDS 18, 695-697.
79. Leclerc, P.M., Dubois-Colas, N. and Garenne, M. (2008) Hormonal contraception and HIV prevalence in four African countries. Contraception 77, 371-376.
80. McCoy, S.I., Zheng, W., Montgomery, E.T., Blanchard, K., van der Straten, A., de Bruyn, G. and Padian, N.S. (2013) Oral and injectable contraception use and risk of HIV acquisition among women in sub-Saharan Africa. AIDS 27, 1001-1009.
81. Gisselquist, D. (2008) Comment on "hormonal contraception and HIV prevalence in four African countries". Contraception 78, 346, author reply 346-347.
82. Stark, K., Poggensee, G., Hohne, M., Bienzle, U., Kiwelu, I. and Schreier, E. (2000) Seroepidemiology of TT virus, GBC-C/HGV, and hepatitis viruses B, C, and E among women in a rural area of Tanzania. J. Med. Virol. 62, 524-530.
83. Ralph, L.J., McCoy, S.I., Shiu, K. and Padian, N.S. (2015) Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies. Lancet Infect. Dis. 15, 181-189.
84. Morrison, C.S., Chen, P.L., Kwok, C., Baeten, J.M., Brown, J., Crook, A.M., Van Damme, L., Delany-Moretlwe, S., Francis, S.C., Friedland, B.A. et al. (2015) Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis. PLoS Med 12, e1001778.
85. Butler, A.R., Smith, J.A., Polis, C.B., Gregson, S., Stanton, D. and Hallett, T.B. (2013) Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk. AIDS 27, 105-113.
86. Jain, A.K. (2012) Hormonal contraception and HIV acquisition risk: implications for individual users and public policies. Contraception 86, 645-652.
87. Whiteman, M.K., Jeng, G., Samarina, A., Akatova, N., Martirosyan, M., Kissin, D.M., Curtis, K.M., Marchbanks, P.A., Hillis, S.D., Mandel, M.G. et al. (2016) Associations of hormonal contraceptive use with measures of HIV disease progression and antiretroviral therapy effectiveness. Contraception 93, 17-24.
88. WHO (2012) Hormonal Contraception and HIV: Technical Statement, WHO
89. (2012) Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of hormonal contraception among women at high risk for HIV infection or infected with HIV Morb. Mortal. Wkly. Rep. 61, 449-452.
90. Michel, K.G., Huijbregts, R.P., Gleason, J.L., Richter, H.E., Hel, Z. (2015) Effect of hormonal contraception on the function of plasmacytoid dendritic cells and distribution of immune cell populations in the female reproductive tract. J. Acquir. Immune Defic. Syndr. 68, 511-518.
91. Huijbregts, R.P., Helton, E.S., Michel, K.G., Sabbaj, S., Richter, H.E., Goepfert, P.A. and Hel, Z. (2013) Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms. Endocrinology 154, 1282-1295.
92. Huijbregts, R.P., Michel, K.G. and Hel, Z. (2014) Effect of progestins on immunity: medroxyprogesterone but not norethisterone or levonorgestrel suppresses the function of T cells and pDCs. Contraception 90, 123-129.
93. Deese, J., Masson, L., Miller, W., Cohen, M., Morrison, C., Wang, M., Ahmed, K., Agot, K., Crucitti, T., Abdellati, S. and Van Damme, L. (2015) Injectable progestin-only contraception is associated with increased levels of pro-inflammatory cytokines in the female genital tract. Am. J. Reprod. Immunol. 74, 357-367.
94. Bahamondes, L., Trevisan, M., Andrade, L., Marchi, N.M., Castro, S., Diaz, J. and Faundes, A. (2000) The effect upon the human vaginal histology of the long-term use of the injectable contraceptive Depo-Provera. Contraception 62, 23-27.
95. Bahamondes, M.V., Castro, S., Marchi, N.M., Marcovici, M., Andrade, L.A., Fernandes, A. and Bahamondes, L. (2014) Human vaginal histology in long-term users of the injectable contraceptive depot-medroxyprogesterone acetate. Contraception 90, 117-122.
96. Ildgruben, A.K., Sjoberg, I.M. and Hammarstrom, M.L. (2003) Influence of hormonal contraceptives on the immune cells and thickness of human vaginal epithelium. Obstet. Gynecol. 102, 571-582.
97. Chandra, N., Thurman, A.R., Anderson, S., Cunningham, T.D., Yousefieh, N., Mauck, C. and Doncel, G.F. (2013) Depot medroxyprogesterone acetate increases immune cell numbers and activation markers in human vaginal mucosal tissues. AIDS Res. Hum. Retroviruses 29, 592-601.
98. Sciaranghella, G., Wang, C., Hu, H., Anastos, K., Merhi, Z., Nowicki, M., Stanczyk, F.Z., Greenblatt, R.M., Cohen, M., Golub, E.T. et al. (2015) CCR5 expression levels in HIV-uninfected women receiving hormonal contraception. J. Infect. Dis. 212, 1397-1401.
99. Ferreira, V.H., Dizzell, S., Nazli, A., Kafka, J.K., Mueller, K., Nguyen, P.V., Tremblay, M.J., Cochrane, A. and Kaushic, C. (2015) Medroxyprogesterone acetate regulates HIV-1 uptake and transcytosis but not replication in primary genital epithelial cells, resulting in enhanced T-cell infection. J. Infect. Dis. 211, 1745-1756.
100. Abel, K., Rourke, T., Lu, D., Bost, K., McChesney, M.B. and Miller, C.J. (2004) Abrogation of attenuated lentivirus-induced protection in rhesus macaques by administration of depo-provera before intravaginal challenge with simian immunodeficiency virus mac239. J. Infect. Dis. 190, 1697-1705.
101. Genesca, M., Li, J., Fritts, L., Chohan, P., Bost, K., Rourke, T., Blozis, S.A., McChesney, M.B. and Miller, C.J. (2007) Depo-Provera abrogates attenuated lentivirus-induced protection in male rhesus macaques challenged intravenously with pathogenic SIVmac239. J. Med. Primatol. 36, 266-275.
102. Genesca, M., McChesney, M.B. and Miller, C.J. (2010) Depo-provera treatment does not abrogate protection from intravenous SIV challenge in female macaques immunized with an attenuated AIDS virus. PLoS One 5, e9814.
103. Trunova, N., Tsai, L., Tung, S., Schneider, E., Harouse, J., Gettie, A., Simon, V., Blanchard, J. and Cheng-Mayer, C. (2006) Progestin-based contraceptive suppresses cellular immune responses in SHIV-infected rhesus macaques. Virology 352, 169-177.
104. Veazey, R.S., Shattock, R.J., Pope, M., Kirijan, J.C., Jones, J., Hu, Q., Ketas, T., Marx, P.A., Klasse, P.J., Burton, D.R. et al. (2003) Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9, 343-346.
105. Marx, P.A., Spira, A.I., Gettie, A., Dailey, P.J., Veazey, R.S., Lackner, A.A., Mahoney, C.J., Miller, C.J., Claypool, L.E., Ho, D.D. et al. (1996) Progesterone implants enhance SIV vaginal transmission and early virus load. Nat. Med. 2, 1084-1089.
106. Veazey, R.S., Shattock, R.J., Klasse, P.J. and Moore, J.P. (2012) Animal models for microbicide studies. Curr. HIV Res. 10, 79-87.
107. Kersh, E.N., Henning, T., Vishwanathan, S.A., Morris, M., Butler, K., Adams, D.R., Guenthner, P., Srinivasan, P., Smith, J., Radzio, J. et al. (2014) SHIV susceptibility changes during the menstrual cycle of pigtail macaques. J. Med. Primatol. 43, 310-316.
108. Radzio, J., Hanley, K., Mitchell, J., Ellis, S., Deyounks, F., Jenkins, L.T., Hanson, D., Heneine, W. and Garcia-Lerma, J.G. (2014) Physiologic doses of depot-medroxyprogesterone acetate do not increase acute plasma simian HIV viremia or mucosal virus shedding in pigtail macaques. AIDS 28, 1431-1439.
109. Vishwanathan, S.A., Guenthner, P.C., Lin, C.Y., Dobard, C., Sharma, S., Adams, D.R., Otten, R.A., Heneine, W., Hendry, R.M., McNicholl, J.M. et al. (2011) High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J. Acquir. Immune Defic. Syndr. 57, 261-264.
110. Hadzic, S.V., Wang, X., Dufour, J., Doyle, L., Marx, P.A., Lackner, A.A., Paulsen, D.B. and Veazey, R.S. (2014) Comparison of the vaginal environment of Macaca mulatta and Macaca nemestrina throughout the menstrual cycle. Am. J. Reprod. Immunol. 71, 322-329.
111. Vishwanathan, S.A., Burgener, A., Bosinger, S.E., Tharp, G.K., Guenthner, P.C., Patel, N.B., Birse, K., Hanson, D.L., Westmacott, G.R., Henning, T. et al. (2015) Cataloguing of potential HIV susceptibility factors during the menstrual cycle of pigtail macaques using a systems biology approach. J. Virol. 89, 9167-9177.
112. Mauck, C.K., Callahan, M.M., Baker, J., Arbogast, K., Veazey, R., Stock, R., Pan, Z., Morrison, C.S., Chen-Mok, M., Archer, D.F. et al. (1999) The effect of one injection of Depo-Provera on the human vaginal epithelium and cervical ectopy. Contraception 60, 15-24.
113. Miller, L., Patton, D.L., Meier, A., Thwin, S.S., Hooton, T.M. and Eschenbach, D.A. (2000) Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium. Obstet. Gynecol. 96, 431-439.
114. Hild-Petito, S., Veazey, R.S., Larner, J.M., Reel, J.R. and Blye, R.P. (1998) Effects of two progestin-only contraceptives, Depo-Provera and Norplant-II, on the vaginal epithelium of rhesus monkeys. AIDS Res. Hum. Retroviruses 14 (Suppl 1), S125-S130.
115. Celum, C.L., Delany-Moretlwe, S., McConnell, M., van Rooyen, H., Bekker, L.G., Kurth, A., Bukusi, E., Desmond, C., Morton, J. and Baeten, J.M. (2015) Rethinking HIV prevention to prepare for oral PrEP implementation for young African women. J. Int. AIDS Soc. 18, 20227.
116. Louissaint, N.A., Cao, Y.J., Skipper, P.L., Liberman, R.G., Tannenbaum, S.R., Nimmagadda, S., Anderson, J.R., Everts, S., Bakshi, R., Fuchs, E.J. et al. (2013) Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue. AIDS Res. Hum. Retroviruses 29, 1443-1450.
117. Patterson, K.B., Prince, H.A., Kraft, E., Jenkins, A.J., Shaheen, N.J., Rooney, J.F., Cohen, M.S. and Kashuba, A.D. (2011) Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci. Transl. Med. 3, 112-114.
118. Dellar, R.C., Dlamini, S. and Karim, Q.A. (2015) Adolescent girls and young women: key populations for HIV epidemic control. J. Int. AIDS Soc. 18, 19408.
119. Maini, M.K., Gilson, R.J., Chavda, N., Gill, S., Fakoya, A., Ross, E.J., Phillips, A.N. and Weller, I.V. (1996) Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. Genitourin Med. 72, 27-31.
120. Tollerud, D.J., Clark, J.W., Brown, L.M., Neuland, C.Y., Pankiw-Trost, L.K., Blattner, W.A. and Hoover, R.N. (1989) The influence of age, race, and gender on peripheral blood mononuclear-cell subsets in healthy nonsmokers. J. Clin. Immunol. 9, 214-222.
121. Collazos, J., Asensi, V. and Carton, J.A. (2007) Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART. AIDS 21, 835-843.
122. Moore, A.L., Kirk, O., Johnson, A.M., Katlama, C., Blaxhult, A., Dietrich, M., Colebunders, R., Chiesi, A., Lungren, J.D. and Phillips, A.N. (2003) Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J. Acquir. Immune Defic. Syndr. 32, 452-461.
123. Nicastri, E., Angeletti, C., Palmisano, L., Sarmati, L., Chiesi, A., Geraci, A., Andreoni, M. and Vella, S. (2005) Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS 19, 577-583.
124. Prins, M., Robertson, J.R., Brettle, R.P., Aguado, I.H., Broers, B., Boufassa, F., Goldberg, D.J., Zangerle, R., Coutinho, R.A. and van den Hoek, A. (1999) Do gender differences in CD4 cell counts matter? AIDS 13, 2361-2364.
125. Mocroft, A., Gill, M.J., Davidson, W. and Phillips, A.N. (2000) Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care? J. Acquir. Immune Defic. Syndr. 24, 475-482.
126. Finkel, D.G., John, G., Holland, B., Slim, J. and Smith, S.M. (2003) Women have a greater immunological response to effective virological HIV-1 therapy. AIDS 17, 2009-2011.
127. Bush, C.E., Donovan, R.M., Markowitz, N., Baxa, D., Kvale, P. and Saravolatz, L.D. (1996) Gender is not a factor in serum human immunodeficiency virus type 1 RNA levels in patients with viremia. J. Clin. Microbiol. 34, 970-972.
128. Richardson, B.A., Mbori-Ngacha, D., Lavreys, L., John-Stewart, G.C., Nduati, R., Panteleeff, D.D., Emery, S., Kreiss, J.K. and Overbaugh, J. (2003) Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection. J. Virol. 77, 7120-7123.
129. Soon, G.G., Min, M., Struble, K.A., Chan-Tack, K.M., Hammerstrom, T., Qi, K., Zhou, S., Bhore, R., Murray, J.S. and Birnkrant, D.B. (2012) Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000-2008). AIDS Patient Care STDS 26, 444-453.
130. Napravnik, S., Poole, C., Thomas, J.C. and Eron, Jr, J.J. (2002) Gender difference in HIV RNA levels: a meta-analysis of published studies. J. Acquir. Immune Defic. Syndr. 31, 11-19.
131. Donnelly, C.A., Bartley, L.M., Ghani, A.C., Le Fevre, A.M., Kwong, G.P., Cowling, B.J., van Sighem, A.I., de Wolf, F., Rode, R.A. and Anderson, R.M. (2005) Gender difference in HIV-1 RNA viral loads. HIV Med. 6, 170-178.
132. Grinsztejn, B., Smeaton, L., Barnett, R., Klingman, K., Hakim, J., Flanigan, T., Kumarasamy, N., Campbell, T. and Currier, J. (2011) Sex-associated differences in pre-antiretroviral therapy plasma HIV-1 RNA in diverse areas of the world vary by CD4(+) T-cell count. Antivir. Ther. 16, 1057-1062.
133. Vrancken, B., Baele, G., Vandamme, A.M., van Laethem, K., Suchard, M.A. and Lemey, P. (2015) Disentangling the impact of within-host evolution and transmission dynamics on the tempo of HIV-1 evolution. AIDS 29, 1549-1556.
134. European Collaborative Study (2002) Level and pattern of HIV-1-RNA viral load over age: differences between girls and boys? AIDS 16, 97-104.
135. Meditz, A.L., Folkvord, J.M., Lyle, N.H., Searls, K., Lie, Y.S., Coakley, E.P., McCarter, M., Mawhinney, S., Connick, E. (2014) CCR5 expression is reduced in lymph nodes of HIV type 1-infected women, compared with men, but does not mediate sex-based differences in viral loads. J. Infect. Dis. 209, 922-930.
136. Meier, A., Chang, J.J., Chan, E.S., Pollard, R.B., Sidhu, H.K., Kulkarni, S., Wen, T.F., Lindsay, R.J., Orellana, L., Mildvan, D. et al. (2009) Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat. Med. 15, 955-959.
137. Shanker, G., Sorci-Thomas, M. and Adams, M.R. (1994) Estrogen modulates the expression of tumor necrosis factor alpha mRNA in phorbol ester-stimulated human monocytic THP-1 cells. Lymphokine Cytokine Res 13, 377-382.
138. Verthelyi, D. (2006) Female's heightened immune status: estrogen, T cells, and inducible nitric oxide synthase in the balance. Endocrinology 147, 659-661.
139. Stoiber, H., Clivio, A. and Dierich, M.P. (1997) Role of complement in HIV infection. Annu. Rev. Immunol. 15, 649-674.
140. Smith-Franklin, B.A., Keele, B.F., Tew, J.G., Gartner, S., Szakal, A.K., Estes, J.D., Thacker, T.C. and Burton, G.F. (2002) Follicular dendritic cells and the persistence of HIV infectivity: the role of antibodies and Fcgamma receptors. J. Immunol. 168, 2408-2414.
141. Kacani, L., Prodinger, W.M., Sprinzl, G.M., Schwendinger, M.G., Spruth, M., Stoiber, H., Dopper, S., Steinhuber, S., Steindl, F. and Dierich, M.P. (2000) Detachment of human immunodeficiency virus type 1 from germinal centers by blocking complement receptor type 2. J. Virol. 74, 7997-8002.
142. Heath, S.L., Tew, J.G., Tew, J.G., Szakal, A.K. and Burton, G.F. (1995) Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 377, 740-744.
143. Gilbert, P., Wang, M., Wrin, T., Petropoulos, C., Gurwith, M., Sinangil, F., D'Souza, P., Rodriguez-Chavez, I.R., DeCamp, A., Giganti, M. et al. (2010) Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J. Infect. Dis. 202, 595-605.
144. Gilbert, P.B., Peterson, M.L., Follmann, D., Hudgens, M.G., Francis, D.P., Gurwith, M., Heyward, W.L., Jobes, D.V., Popovic, V., Self, S.G. et al. (2005) Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis. 191, 666-677.
145. Haase, A.T., Henry, K., Zupancic, M., Sedgewick, G., Faust, R.A., Melroe, H., Cavert, W., Gebhard, K., Staskus, K., Zhang, Z.Q. et al. (1996) Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 274, 985-989.
146. Floridia, M., Giuliano, M., Palmisano, L. and Vella, S. (2008) Gender differences in the treatment of HIV infection. Pharmacol. Res. 58, 173-182.
147. Ofotokun, I. and Pomeroy, C. (2003) Sex differences in adverse reactions to antiretroviral drugs. Top. HIV Med. 11, 55-59.
148. Currier, J., Averitt Bridge, D., Hagins, D., Zorrilla, C.D., Feinberg, J., Ryan, R., Falcon, R., Tennenberg, A., Mrus, J. and Squires, K. (2010) Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann. Intern. Med. 153, 349-357.
149. Aziz, M. and Smith, K.Y. (2012) Treating women with HIV: is it different than treating men? Curr. HIV/AIDS Rep 9, 171-178.
150. Bonfanti, P., Valsecchi, L., Parazzini, F., Carradori, S., Pusterla, L., Fortuna, P., Timillero, L., Alessi, F., Ghiselli, G., Gabbuti, A. et al. (2000) Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. J. Acquir. Immune Defic. Syndr. 23, 236-245.
151. Gatti, G., Di Biagio, A., Casazza, R., De Pascalis, C., Bassetti, M., Cruciani, M., Vella, S. and Bassetti, D. (1999) The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS 13, 2083-2089.
152. Lucas, G.M., Chaisson, R.E. and Moore, R.D. (1999) Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann. Intern. Med. 131, 81-87.
153. Cressey, T.R. and Lallemant, M. (2007) Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update. Infect. Genet. Evol. 7, 333-342.
154. Umeh, O.C. and Currier, J.S. (2006) Sex differences in pharmacokinetics and toxicity of antiretroviral therapy. Expert Opin. Drug Metab. Toxicol. 2, 273-283.
155. Nicolson, T.J., Mellor, H.R. and Roberts, R.R. (2010) Gender differences in drug toxicity. Trends Pharmacol. Sci. 31, 108-114.
156. Gandhi, M., Aweeka, F., Greenblatt, R.M. and Blaschke, T.F. (2004) Sex differences in pharmacokinetics and pharmacodynamics. Annu. Rev. Pharmacol. Toxicol. 44, 499-523.
157. Ofotokun, I., Chuck, S.K. and Hitti, J.E. (2007) Antiretroviral pharmacokinetic profile: a review of sex differences. Gend. Med. 4, 106-119.
158. Prins, M., Meyer, L. and Hessol, N.A. (2005) Sex and the course of HIV infection in the pre- and highly active antiretroviral therapy eras. AIDS 19, 357-370.
159. Kuyper, L.M., Wood, E., Montaner, J.S., Yip, B., O'Connell, J.M. and Hogg, R.S. (2004) Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-Infected patients in a population-based cohort. J. Acquir. Immune Defic. Syndr. 37, 1470-1476.
160. Lawn, S.D., Butera, S.T. and Folks, T.M. (2001) Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin. Microbiol. Rev. 14, 753-777.
161. Hazenberg, M.D., Otto, S.A., van Benthem, B.H., Roos, M.T., Coutinho, R.A., Lange, J.M., Hamann, D., Prins, M. and Miedema, F. (2003) Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 17, 1881-1888.
162. Giorgi, J.V., Hultin, L.E., McKeating, J.A., Johnson, T.D., Owens, B., Jacobson, L.P., Shih, R., Lewis, J., Wiley, D.J., Phair, J.P. et al. (1999) Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J. Infect. Dis. 179, 859-870.
163. El-Sadr, W.M., Lundgren, J., Neaton, J.D., Gordin, F., Abrams, D., Arduino, R.C., Babiker, A., Burman, W., Clumeck, N., Cohen, C.J. et al. (2006) CD4+ count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 355, 2283-2296.
164. Hunt, P.W., Martin, J.N., Sinclair, E., Bredt, B., Hagos, E., Lampiris, H. and Deeks, S.G. (2003) T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J. Infect. Dis. 187, 1534-1543.
165. Lekakis, J. and Ikonomidis, I. (2010) Cardiovascular complications of AIDS. Curr. Opin. Crit. Care 16, 408-412.
166. Lichtenstein, K.A., Armon, C., Buchacz, K., Chmiel, J.S., Buckner, K., Tedaldi, E.M., Wood, K., Holmberg, S.D. and Brooks, J.T. (2010) Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin. Infect. Dis. 51, 435-447.
167. Ho, J.E., Deeks, S.G., Hecht, F.M., Xie, Y., Schnell, A., Martin, J.N., Ganz, P. and Hsue, P.Y. (2010) Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals. AIDS 24, 1897-1905.
168. Baker, J.V. and Duprez, D. (2010) Biomarkers and HIV-associated cardiovascular disease. Curr. Opin. HIV AIDS 5, 511-516.
169. Biancotto, A., Grivel, J.C., Iglehart, S.J., Vanpouille, C., Lisco, A., Sieg, S.F., Debernardo, R., Garate, K., Rodriguez, B., Margolis, L.B. et al. (2007) Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood 109, 4272-4279.
170. Brenchley, J.M., Price, D.A., Schacker, T.W., Asher, T.E., Silvestri, G., Rao, S., Kazzaz, Z., Bornstein, E., Lambotte, O., Altmann, D. et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12, 1365-1371.
171. Gonzalez, V.D., Falconer, K., Blom, K.G., Reichard, O., Morn, B., Laursen, A.L., Weis, N., Alaeus, A. and Sandberg, J.K. (2009) High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. J. Virol. 83, 11407-11411.
172. Jiang, W., Lederman, M.M., Hunt, P., Sieg, S.F., Haley, K., Rodriguez, B., Landay, A., Martin, J., Sinclair, E., Asher, A.I. et al. (2009) Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J. Infect. Dis. 199, 1177-1185.
173. Ren, W., Ma, Y., Yang, L., Gettie, A., Salas, J., Russell, K., Blanchard, J., Davidow, A., Pei, Z., Chang, T.L. et al. (2015) Fast disease progression in simian HIV-infected female macaque is accompanied by a robust local inflammatory innate immune and microbial response. AIDS 29, F1-F8.
174. O'Brien, M., Manches, O. and Bhardwaj, N. (2013) Plasmacytoid dendritic cells in HIV infection. Adv. Exp. Med. Biol. 762, 71-107.
175. Beignon, A.S., McKenna, K., Skoberne, M., Manches, O., DaSilva, I., Kavanagh, D.G., Larsson, M., Gorelick, R.J., Lifson, J.D. and Bhardwaj, N. (2005) Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J. Clin. Invest. 115, 3265-3275.
176. Bjorck, P. (2004) Dendritic cells exposed to herpes simplex virus in vivo do not produce IFN-alpha after rechallenge with virus in vitro and exhibit decreased T cell alloreactivity. J. Immunol. 172, 5396-5404.
177. Ito, T., Kanzler, H., Duramad, O., Cao, W. and Liu, Y.J. (2006) Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells. Blood 107, 2423-2431.
178. O'Brien, M., Manches, O., Sabado, R.L., Baranda, S.J., Wang, Y., Marie, I., Rolnitzky, L., Markowitz, M., Margolis, D.M., Levy, D. et al. (2011) Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-alpha-producing and partially matured phenotype. J. Clin. Invest. 121, 1088-1101.
179. Haase, A.T. (2010) Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464, 217-223.
180. Boasso, A., Hardy, A.W., Anderson, S.A., Dolan, M.J. and Shearer, G.M. (2008) HIV-induced type I interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activation. PLoS One 3, e2961.
181. Favre, D., Mold, J., Hunt, P.W., Kanwar, B., Loke, P., Seu, L., Barbour, J.D., Lowe, M.M., Jayawardene, A., Aweeka, F. et al. (2010) Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci. Transl. Med. 2, 32-36.
182. Manches, O., Munn, D., Fallahi, A., Lifson, J., Chaperot, L., Plumas, J. and Bhardwaj, N. (2008) HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. J. Clin. Invest. 118, 3431-3439.
183. Jacquelin, B., Mayau, V., Targat, B., Liovat, A.S., Kunkel, D., Petitjean, G., Dillies, M.A., Roques, P., Butor, C., Silvestri, G. et al. (2009) Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J. Clin. Invest. 119, 3544-3555.
184. Bosinger, S.E., Li, Q., Gordon, S.N., Klatt, N.R., Duan, L., Xu, L., Francella, N., Sidahmed, A., Smith, A.J., Cramer, E.M. et al. (2009) Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J. Clin. Invest. 119, 3556-3572.
185. Chang, J.J., Woods, M., Lindsay, R.J., Doyle, E.H., Griesbeck, M., Chan, E.S., Robbins, G.K., Bosch, R.J. and Altfeld, M. (2013) Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication. J. Infect. Dis. 208, 830-838.
186. Berghofer, B., Frommer, T., Haley, G., Fink, L., Bein, G. and Hackstein, H. (2006) TLR7 ligands induce higher IFN-alpha production in females. J. Immunol. 177, 2088-2096.
187. Seillet, C., Laffont, S., Tremollieres, F., Rouquie, N., Ribot, C., Arnal, J.F., Douin-Echinard, V., Gourdy, P. and Guery, J.C. (2012) The TLR-mediated response of plasmacytoid dendritic cells is positively regulated by estradiol in vivo through cell-intrinsic estrogen receptor alpha signaling. Blood 119, 454-464.
188. Griesbeck, M., Ziegler, S., Laffont, S., Smith, N., Chauveau, L., Tomezsko, P., Sharei, A., Kourjian, G., Porichis, F., Hart, M. et al. (2015) Sex differences in plasmacytoid dendritic cell levels of IRF5 drive higher IFN-alpha production in women. J. Immunol. 195, 5327-5336.
189. Krebs, S.J. and Ananworanich, J. (2016) Immune activation during acute HIV infection and the impact of early antiretroviral therapy. Curr. Opin. HIV AIDS 11, 163-172.
190. Massanella, M., Fromentin, R. and Chomont, N. (2016) Residual inflammation and viral reservoirs: alliance against an HIV cure. Curr. Opin. HIV AIDS 11, 234-241.
191. Cuzin, L., Pugliese, P., Saune, K., Allavena, C., Ghosn, J., Cottalorda, J., Rodallec, A., Chaix, M.L., Fafi-Kremer, S., Soulie, C. et al. (2015) Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy. AIDS 29, 1665-1671.
192. Olesen, R., Vigano, S., Rasmussen, T.A., Sogaard, O.S., Ouyang, Z., Buzon, M., Bashirova, A., Carrington, M., Palmer, S., Brinkmann, C.R. et al. (2015) Innate immune activity correlates with CD4 T cell-associated HIV-1 DNA decline during latency-reversing treatment with panobinostat. J. Virol. 89, 10176-10189.
193. Szotek, E.L., Narasipura, S.D. and Al-Harthi, L. (2013) 17beta-Estradiol inhibits HIV-1 by inducing a complex formation between beta-catenin and estrogen receptor alpha on the HIV promoter to suppress HIV transcription. Virology 443, 375-383.
194. Karn, J. (2015) Estrogen blocks HIV re-emergence from latency and points to gender-specific differences in HIV reservoirs. In International AIDS Society 2015, Vancouver
195. Mirkin, S. and Pickar, J.H. (2015) Selective estrogen receptor modulators (SERMs): a review of clinical data. Maturitas 80, 52-57.
196. Komm, B.S. and Mirkin, S. (2014) An overview of current and emerging SERMs. J. Steroid Biochem. Mol. Biol. 143, 207-222.
197. Johnston, R.E. and Heitzeg, M.M. (2015) Sex, age, race and intervention type in clinical studies of HIV cure: a systematic review. AIDS Res. Hum. Retroviruses 31, 85-97.
198. Siddiqui, R.A., Sauermann, U., Altmuller, J., Fritzer, E., Nothnagel, M., Dalibor, N., Fellay, J., Kaup, F.J., Stahl-Hennig, C., Nurnberg, P. et al. (2009) X chromosomal variation is associated with slow progression to AIDS in HIV-1-infected women. Am. J. Hum. Genet. 85, 228-239.